Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1961 1
1963 2
1964 2
1965 1
1966 3
1967 1
1969 5
1970 6
1971 15
1972 5
1973 4
1974 6
1975 1
1977 1
1978 3
1979 1
1980 2
1981 5
1982 2
1983 5
1984 5
1985 6
1986 2
1987 3
1989 4
1990 7
1991 2
1992 4
1993 4
1994 2
1995 3
1996 5
1997 4
1998 3
1999 5
2000 3
2001 5
2002 5
2003 5
2004 4
2005 7
2006 7
2007 10
2008 9
2009 9
2010 4
2011 9
2012 15
2013 11
2014 10
2015 11
2016 12
2017 12
2018 12
2019 12
2020 31
2021 38
2022 26
2023 20
2024 28
2025 42
2026 28

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

468 results

Results by year

Filters applied: . Clear all
Page 1
Human iPSC-liver organoid transplantation reduces fibrosis through immunomodulation.
Tadokoro T, Murata S, Kato M, Ueno Y, Tsuchida T, Okumura A, Kuse Y, Konno T, Uchida Y, Yamakawa Y, Zushi M, Yajima M, Kobayashi T, Hasegawa S, Kawakatsu-Hatada Y, Hayashi Y, Osakabe S, Maeda T, Kimura K, Mori A, Tanaka M, Kamishibahara Y, Matsuo M, Nie YZ, Okamoto S, Oba T, Tanimizu N, Taniguchi H. Tadokoro T, et al. Among authors: oba t. Sci Transl Med. 2024 Jul 24;16(757):eadg0338. doi: 10.1126/scitranslmed.adg0338. Epub 2024 Jul 24. Sci Transl Med. 2024. PMID: 39047116
Placenta-derived factors contribute to human iPSC-liver organoid growth.
Kuse Y, Matsumoto S, Tsuzuki S, Carolina E, Okumura T, Kasai T, Yamabe S, Yamaguchi K, Furukawa Y, Tadokoro T, Ueno Y, Oba T, Tanimizu N, Taniguchi H. Kuse Y, et al. Among authors: oba t. Nat Commun. 2025 Mar 13;16(1):2493. doi: 10.1038/s41467-025-57551-w. Nat Commun. 2025. PMID: 40082402 Free PMC article.
Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1 < 1 %: A multicenter, retrospective study.
Murata D, Azuma K, Murotani K, Ito K, Nomizo T, Yamada K, Imabayashi T, Iwanaga K, Chibana K, Ota T, Nishii Y, Nakao A, Okada A, Hamai K, Tanimura K, Yoshimine K, Tamura Y, Takaki R, Goto Y, Hibino M, Oba T, Sumi T, Kaneda H, Nishioka N, Yamada T, Takayama K. Murata D, et al. Among authors: oba t. Lung Cancer. 2025 Nov;209:108772. doi: 10.1016/j.lungcan.2025.108772. Epub 2025 Sep 26. Lung Cancer. 2025. PMID: 41046781
Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01.
Tanaka H, Makiguchi T, Tozuka T, Kawashima Y, Oba T, Tsugitomi R, Koyama J, Tambo Y, Ogusu S, Saiki M, Gyotoku H, Hasegawa T, Miyauchi E, Sonoda T, Saito R, Nakatomi K, Sakatani T, Kudo K, Tsuchiya-Kawano Y, Nishio M. Tanaka H, et al. Among authors: oba t. Eur J Cancer. 2024 Dec;213:115117. doi: 10.1016/j.ejca.2024.115117. Epub 2024 Nov 5. Eur J Cancer. 2024. PMID: 39522333 Free article.
Efficacy and Safety of Chemoimmunotherapy in Patients With Advanced Non-small Cell Lung Cancer With Pre-existing Interstitial Pneumonia and Low PD-L1 Expression.
Sasada A, Kawachi H, Yamada T, Hata T, Goto Y, Amano A, Negi Y, Watanabe S, Furuya N, Oba T, Ikoma T, Nakao A, Tanimura K, Taniguchi H, Yoshimura A, Fukui T, Murata D, Kaira K, Shiotsu S, Okada A, Chihara Y, Kijima T, Takayama K. Sasada A, et al. Among authors: oba t. Anticancer Res. 2025 Nov;45(11):5045-5057. doi: 10.21873/anticanres.17845. Anticancer Res. 2025. PMID: 41151889
Analysis of Poor Prognostic Factors and Treatment Strategies in Platinum-Based Systemic Therapy After EGFR-TKI Failure in Patients With Advanced Nonsmall Cell Lung Cancer Harboring EGFR Mutations.
Hata T, Yamada T, Furuya N, Tanaka H, Yoshimura A, Oba T, Hibino M, Fukuda T, Goto Y, Nakao A, Ogusu S, Okazaki Y, Harada T, Ota T, Masubuchi K, Mikami K, Matsumoto S, Honda R, Date K, Chihara Y, Kawachi H, Morimoto K, Takayama K. Hata T, et al. Among authors: oba t. Clin Lung Cancer. 2025 Dec;26(8):e639-e648. doi: 10.1016/j.cllc.2025.07.014. Epub 2025 Jul 22. Clin Lung Cancer. 2025. PMID: 40816949
Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED).
Ishihara M, Kawamura T, Namba Y, Takeyasu Y, Hasegawa Y, Sato Y, Negi Y, Oba T, Sumi T, Hirata H, Funabashi H, Oya Y, Kikuchi H, Katsurada N, Nakatani T, Tanimura K, Nakagawa T, Takeda N, Asami T, Honjo O, Nagashima H, Yamaura T, Hata N, Kitazono M, Nishioka N, Tamiya A, Sakamori Y, Shigaki R, Kaira K, Honda R, Matsui T, Suzuki E, Ito K, Otsuka K, Takase N, Murakami Y, Matsuno K, Inoue S, Kisohara A, Kusumoto S, Aoshima H, Kakizaki Y, Kubo A, Hata A, Ishikawa N, Hamai K, Kanaji N, Misumi T, Matsutani N, Seki N. Ishihara M, et al. Among authors: oba t. Ther Adv Med Oncol. 2025 Jun 16;17:17588359251344010. doi: 10.1177/17588359251344010. eCollection 2025. Ther Adv Med Oncol. 2025. PMID: 40535732 Free PMC article.
Impact of Glucocorticoids on Immune Checkpoint Inhibitor Efficacy and Circulating Biomarkers in Non-Small Cell Lung Cancer Patients.
Polyakov L, Lim A, Meyer A, Mades A, Ni J, Cooper R, Ye S, Kajihara R, Oba T, Contreras L, Abdelfatah E, Sarkar J, Matsuzaki J, Li M, Sharma R, Segal BH, Hsu RC, Chen H, Nieva J, Ito F. Polyakov L, et al. Among authors: oba t. Cancer Res Commun. 2025 Jul 1;5(7):1082-1094. doi: 10.1158/2767-9764.CRC-25-0051. Cancer Res Commun. 2025. PMID: 40622275 Free PMC article.
Lenvatinib for patients with previously treated advanced thymic carcinoma in real-world settings.
Takagi K, Saito G, Tanaka H, Kubo S, Shukuya T, Tsugitomi R, Sasaki T, Oba T, Mamesaya N, Yamanaka T, Tachihara M, Gyotoku H, Nagashima H, Tamiya M, Kanemura H, Tozuka T, Furuta M, Sakata S, Mouri A, Miwa H, Kawachi H, Ninomiya T, Nagai Y, Ogino H, Ito K, Tamura Y, Tokito T, Ishihara M, Ashinuma H, Tsukita Y, Kogure Y, Masuda T, Suzuki T. Takagi K, et al. Among authors: oba t. ESMO Open. 2025 Jun;10(6):105301. doi: 10.1016/j.esmoop.2025.105301. Epub 2025 Jun 1. ESMO Open. 2025. PMID: 40456188 Free PMC article.
468 results